# Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

> **NCT00640471** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 750 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** brivanib alaninate

## Key facts

- **NCT ID:** NCT00640471
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-12
- **Primary completion:** 2011-09-06
- **Final completion:** 2013-01-10
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640471, "Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00640471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*